STTK (Shattuck Labs, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by STTK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-07 | Abhinav A. Shukla | Chief Technical Officer | MIXED | — | — |
| 2026-07-02 | Arundathy N. Pandite | Chief Medical Officer | Sell | — | — |
| 2026-07-02 | Abhinav A. Shukla | Chief Technical Officer | MIXED | — | — |
| 2026-06-15 | Mona Ashiya | Director | Buy | — | — |
| 2026-06-15 | OrbiMed Genesis GP LLC | Director | Buy | — | — |
| 2026-06-11 | CLAY B SIEGALL | Director | Buy | — | — |
| 2026-06-09 | Mona Ashiya | Director | C | — | — |
| 2026-06-09 | OrbiMed Genesis GP LLC | Director | C | — | — |
| 2026-06-02 | Helen M Boudreau | Director | A | — | — |
| 2026-06-02 | Neil W Gibson | Director | A | — | — |
| 2026-06-02 | Daniel G. Baker | Director | A | — | — |
| 2026-06-02 | Mona Ashiya | Director | A | — | — |
| 2026-06-02 | George Golumbeski | Director | A | — | — |
| 2026-06-02 | CLAY B SIEGALL | Director | A | — | — |
| 2026-05-27 | CLAY B SIEGALL | Director | A | — | — |
| 2026-05-21 | Abhinav A. Shukla | Chief Technical Officer | A | — | — |
| 2026-05-18 | Stephen Stout | See Remarks | A | — | — |
| 2026-05-14 | Arundathy N. Pandite | Chief Medical Officer | Sell | — | — |
| 2026-05-14 | Abhinav A. Shukla | Chief Technical Officer | MIXED | — | — |
| 2026-05-14 | Andrew R Neill | Chief Financial Officer | A | — | — |
| 2026-05-13 | Taylor Schreiber | Chief Executive Officer | A | — | — |
| 2026-05-12 | Stephen Stout | See Remarks | F | — | — |
| 2026-01-27 | Stephen Stout | See Remarks | F | — | — |
| 2026-01-27 | Casi DeYoung | Chief Business Officer | F | — | — |
| 2026-01-27 | Andrew R Neill | Chief Financial Officer | F | — | — |
| 2026-01-27 | Arundathy N. Pandite | Chief Medical Officer | F | — | — |
| 2026-01-13 | Abhinav A. Shukla | Chief Technical Officer | A | — | — |
| 2026-01-13 | Stephen Stout | See Remarks | F | — | — |
| 2026-01-13 | Casi DeYoung | Chief Business Officer | F | — | — |
| 2026-01-13 | Andrew R Neill | Chief Financial Officer | F | — | — |
| 2026-01-13 | Taylor Schreiber | Chief Executive Officer | A | — | — |
| 2026-01-13 | Arundathy N. Pandite | Chief Medical Officer | F | — | — |
| 2025-09-02 | Mona Ashiya | Director | A | — | — |
| 2025-09-02 | Daniel G. Baker | Director | A | — | — |
| 2025-09-02 | OrbiMed Capital GP IX LLC | Director | Buy | — | — |
| 2025-09-02 | Mona Ashiya | Director | Buy | — | — |
| 2025-08-27 | Stephen Stout | See Remarks | A | — | — |
| 2025-08-27 | Taylor Schreiber | Chief Executive Officer | A | — | — |
| 2025-08-27 | Abhinav A. Shukla | Chief Technical Officer | A | — | — |
| 2025-08-27 | Andrew R Neill | Chief Financial Officer | A | — | — |
| 2025-08-27 | CLAY B SIEGALL | Director | A | — | — |
| 2025-08-26 | Jeremy Green | Director | A | — | — |
| 2025-07-16 | Amy Kate Sasser | Director | A | — | — |
| 2025-07-16 | CLAY B SIEGALL | Director | A | — | — |
| 2025-07-16 | Jeremy Green | Director | A | — | — |
| 2025-07-16 | Tyler Brous | Director | A | — | — |
| 2025-07-16 | Michael Stewart Lee | Director | A | — | — |
| 2025-07-16 | Neil W Gibson | Director | A | — | — |
| 2025-07-16 | George Golumbeski | Director | A | — | — |
| 2025-07-16 | Carrie Brownstein | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 5,615,489 | — |
| — | Director | 5,539,724 | — |
| — | Chief Executive Officer | 2,732,972 | — |
| — | Director | 1,051,021 | — |
| — | Director | 1,051,021 | — |
| — | Director | 1,051,021 | — |
| — | Director | 318,608 | — |
| — | Chief Financial Officer | 292,251 | — |
| — | Director | 267,731 | — |
| — | Director | 235,088 | — |
| — | Chief Medical Officer | 136,219 | — |
| — | General Counsel | 103,209 | — |
| — | Chief Technical Officer | 98,533 | — |
| — | See Remarks | 93,366 | — |
| — | Chief Business Officer | 73,480 | — |
| — | Director | 54,613 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the STTK quote page; the site-wide leaderboard is on the insider transactions hub.